Therapy News and Research

RSS

Par Pharmaceutical starts shipping generic version of Exforge

Par Pharmaceutical Companies, Inc. today announced that it has begun shipping all four strengths of amlodipine and valsartan tablets, the generic version of Novartis' Exforge. Par received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for amlodipine and valsartan and was granted 180 days of marketing exclusivity.

30 Sep 2014

Trastuzumab offers better outcome than lapatinib for HER2-positive breast cancer patients

Analysis of more than 8,000 women who participated in the world's largest study of two treatments for HER2-positive breast cancer reinforces other findings from the clinical trial showing that trastuzumab (Herceptin) should remain the standard of care for this cancer, says a Mayo Clinic researcher.

30 Sep 2014

TSRI study points way to potential therapies for hereditary spastic paraplegia

Scientists at The Scripps Research Institute have discovered that a gene mutation linked to hereditary spastic paraplegia, a disabling neurological disorder, interferes with the normal breakdown of triglyceride fat molecules in the brain. The TSRI researchers found large droplets of triglycerides within the neurons of mice modeling the disease.

30 Sep 2014

Cedars-Sinai experts to present free conference on dystonia for patients, families and caregivers

A multidisciplinary team of experts affiliated with the Cedars-Sinai Movement Disorders Program will present a free conference for patients, families and caregivers on treatment options for dystonia, which causes painful and potentially crippling muscle contractions.

30 Sep 2014

Research finding opens door to potential treatment for MPS IIIB

MPS IIIB is a devastating and currently untreatable disease that causes progressive damage to the brain, leading to profound intellectual disability, dementia and death -- often before reaching adulthood.

30 Sep 2014

Phase 3 COU-AA-302 results show ZYTIGA plus prednisone prolongs overall survival in men with chemotherapy-naive mCRPC

A final analysis of the Phase 3 COU-AA-302 trial presented today at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid, Spain showed that ZYTIGA® (abiraterone acetate) plus prednisone significantly prolonged overall survival (OS), compared to an active control of placebo plus prednisone, in men with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC).

30 Sep 2014

PD-L1 protein could be a potential immunotherapy target for malignant pleural mesothelioma

Treating patients with high-dose radiotherapy after chemotherapy and surgery for malignant pleural mesothelioma does not achieve improvements in local relapse and overall survival, according to data from a prospective randomized phase II trial presented at ESMO 2014 Congress in Madrid.

30 Sep 2014

Bausch + Lomb’s sub-micron loteprednol etabonate ophthalmic gel meets primary endpoint

Bausch + Lomb, a wholly owned subsidiary of Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX), today announced that its next generation sub-micron gel formulation of loteprednol etabonate was statistically superior to placebo (vehicle gel) in eliminating inflammation and pain following cataract surgery by study day eight, the primary endpoints in the first Phase 3, multi-center, double-masked, vehicle-controlled, parallel-group study.

30 Sep 2014

Pertuzumab combined with trastuzumab and chemotherapy extends lives of HER2-positive breast cancer patients

Patients with HER2-positive breast cancer that has spread to other parts of their body live around 16 months longer if treated with a combination of pertuzumab, trastuzumab and chemotherapy compared to those treated with trastuzumab and chemotherapy alone, updated results from the CLEOPATRA study reveal.

30 Sep 2014

CFDA clears Elekta's Versa HD radiation therapy system

Following US and European approvals of Elekta's Versa HD™ linear accelerator, the China Food and Drug Administration (CFDA) has cleared the radiation therapy system for sale and marketing in the country.

From Elekta 30 Sep 2014

Nivolumab drug achieves superior response rates in previously-treated advanced melanoma patients

The monoclonal antibody nivolumab achieves superior response rates and a longer duration of response than standard chemotherapy in patients whose melanoma has progressed after treatment with ipilimumab, according to phase III data presented at the ESMO 2014 Congress in Madrid, Spain.

30 Sep 2014

Combination therapy achieves greater progression-free survival, response rates in melanoma

Combination therapy with both BRAF inhibitor vemurafenib and MEK inhibitor cobimetinib achieves greater progression-free survival and response rates than vemurafenib plus placebo in BRAF-mutation positive melanoma, according to phase III data presented at the ESMO 2014 Congress in Madrid, Spain.

30 Sep 2014

Antibiotic exposure in infancy linked to childhood obesity

Repeated exposure to broad-spectrum antibiotics in the first two years of life is associated with early childhood obesity, say researchers from The Children's Hospital of Philadelphia in a retrospective study based on data from electronic health records from the extensive CHOP Care Network.

30 Sep 2014

Targeted treatments may improve idiopathic PAH survival

Patients with idiopathic pulmonary arterial hypertension may live longer if they are given targeted treatments than if they receive conventional management, researchers suggest.

29 Sep 2014

Neuropsychiatric symptoms variable in early Parkinson’s disease

The prevalence of neuropsychiatric symptoms is increased in patients with early Parkinson’s disease, although many remain stable over time, shows follow-up of the Parkinson’s Progression Markers Initiative.

29 Sep 2014

Increasing prevalence of obstructive sleep apnea threatens public health and safety

Public health and safety are threatened by the increasing prevalence of obstructive sleep apnea, which now afflicts at least 25 million adults in the U.S., according to the National Healthy Sleep Awareness Project. Several new studies highlight the destructive nature of obstructive sleep apnea, a chronic disease that increases the risk of high blood pressure, heart disease, Type 2 diabetes, stroke and depression.

29 Sep 2014

Targeted combination drug therapy can extend life, halt disease in metastatic melanoma patients

A world-first study in today's New England Journal of Medicine heralds the efficacy of a targeted combination drug therapy after reporting major declines in the risk of disease progression and death in people with metastatic melanoma.

29 Sep 2014

Spring Mountain Capital leads financing round for Oncoceutics with additional private investors' participation

Spring Mountain Capital, LP, a New York-based investment management firm, announced today that its private equity group structured and led a financing round for Oncoceutics, Inc. with additional private investors' participation.

29 Sep 2014

HerKare opens new location in Mansfield, Texas

HerKare opens a new location today in Mansfield, Texas. This marks HerKare's third center in Dallas-Fort Worth. HerKare recently expanded to Houston area and continues to accelerate their growth plans, making the treatment of hormonal imbalance in women more convenient.

29 Sep 2014

Curemark Founder to get Northstar Award for breakthrough autism research

Curemark, a leading drug research and development company focused on the treatment of neurological and other diseases, is proud to announce that Dr. Joan Fallon, Founder and CEO, will receive Springboard Enterprises' Northstar Award, as recognition for her entrepreneurial leadership and achievements in autism research.

29 Sep 2014

Therapy News and Research

Par Pharmaceutical starts shipping generic version of Exforge

Trastuzumab offers better outcome than lapatinib for HER2-positive breast cancer patients

TSRI study points way to potential therapies for hereditary spastic paraplegia

Cedars-Sinai experts to present free conference on dystonia for patients, families and caregivers

Research finding opens door to potential treatment for MPS IIIB

Phase 3 COU-AA-302 results show ZYTIGA plus prednisone prolongs overall survival in men with chemotherapy-naive mCRPC

PD-L1 protein could be a potential immunotherapy target for malignant pleural mesothelioma

Bausch + Lomb’s sub-micron loteprednol etabonate ophthalmic gel meets primary endpoint

Pertuzumab combined with trastuzumab and chemotherapy extends lives of HER2-positive breast cancer patients

CFDA clears Elekta's Versa HD radiation therapy system

Nivolumab drug achieves superior response rates in previously-treated advanced melanoma patients

Combination therapy achieves greater progression-free survival, response rates in melanoma

Antibiotic exposure in infancy linked to childhood obesity

Targeted treatments may improve idiopathic PAH survival

Neuropsychiatric symptoms variable in early Parkinson’s disease

Increasing prevalence of obstructive sleep apnea threatens public health and safety

Targeted combination drug therapy can extend life, halt disease in metastatic melanoma patients

Spring Mountain Capital leads financing round for Oncoceutics with additional private investors' participation

HerKare opens new location in Mansfield, Texas

Curemark Founder to get Northstar Award for breakthrough autism research

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News